Kylie Baldwin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kylie Baldwin has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Minson
Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia
2 shared publications - Brydon Panozzo
Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia
2 shared publications - Constantine S. Tam
Alfred Health and Monash University, East Melbourne, Australia
2 shared publications David A. Westerman
Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
2 shared publicationsJian Li
Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, VIC, Australia
2 shared publications- John Francis Seymour
Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Australia
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Wiley in British Journal of Haematology
CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications
Summary: Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the prevalence of CD20‐negative CLL in patients treated with fixed‐duration venetoclax/obinutuzumab (Ven‐O) or venetoclax/rituximab (Ven‐R). CD20 expression was assessed by flow cytometry at baseline, end of treatment (EOT) and disease progression, with negativity defined if the log difference in median fluorescence intensity (MFI) between CLL cells and T‐cell controls was less than 0.5. Of 60 patients, (34 Ven‐O, 26 Ven‐R), 6 demonstrated pre‐therapy CD20 negativity (1 treatment‐naïve, 5 pre‐treated) and 10/29 (34%) with measurable residual disease (MRD) at EOT demonstrated post‐therapy CD20 loss (4 Ven‐O, 6 Ven‐R). Notch receptor 1 ( NOTCH1 ) variants were identified in 5/10 (50%) patients with CD20‐negative MRD, compared to 3/18 (17%) with CD20‐positive MRD and 6/29 (21%) with undetectable MRD. Five patients had longitudinal assessment, with all demonstrating persistent CD20‐negative disease long after antibody exposure (follow‐up 12–39 months). These results have potential implications for future treatment selection and efficacy.
- 16 November 2026
- Published by Wiley in British Journal of Haematology
Open AccessCD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications
Summary: Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the prevalence of CD20‐negative CLL in patients treated with fixed‐duration venetoclax/obinutuzumab (Ven‐O) or venetoclax/rituximab (Ven‐R). CD20 expression was assessed by flow cytometry at baseline, end of treatment (EOT) and disease progression, with negativity defined if the log difference in median fluorescence intensity (MFI) between CLL cells and T‐cell controls was less than 0.5. Of 60 patients, (34 Ven‐O, 26 Ven‐R), 6 demonstrated pre‐therapy CD20 negativity (1 treatment‐naïve, 5 pre‐treated) and 10/29 (34%) with measurable residual disease (MRD) at EOT demonstrated post‐therapy CD20 loss (4 Ven‐O, 6 Ven‐R). Notch receptor 1 ( NOTCH1 ) variants were identified in 5/10 (50%) patients with CD20‐negative MRD, compared to 3/18 (17%) with CD20‐positive MRD and 6/29 (21%) with undetectable MRD. Five patients had longitudinal assessment, with all demonstrating persistent CD20‐negative disease long after antibody exposure (follow‐up 12–39 months). These results have potential implications for future treatment selection and efficacy.
- 16 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7018-7022
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL
- 16 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7018-7022
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL
- Open Access
- 7 September 2026
- Published by Wiley in British Journal of Haematology
Dynamic risk stratification using early CAR ‐T expansion in R/R LBCL treated with axicabtagene ciloleucel
Summary: The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T‐cell expansion post‐infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B‐cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi‐cel). CAR T‐cell expansion was measured by flow cytometry at days 7, 14 and 28 following infusion with real‐time reporting to the clinical service in 111 patients. We examined the association between CAR T‐cell expansion, efficacy (progression‐free survival [PFS]), toxicity (cytokine release syndrome [CRS] and immune effector cell‐associated neurotoxicity syndrome [ICANS]) and toxicity management, accounting for baseline risk factors. A multivariable model combining day 7 expansion with pre‐lymphodepletion lactate dehydrogenase (LDH) and bridging response demonstrated that robust day 7 expansion (≥48 cells/μL) was independently associated with improved PFS (hazard ratio [HR], 0.43; 95% confidence interval [CI] 0.22–0.83; p = 0.01). Higher day 7 expansion was associated with increased CRS severity and ICANS incidence. Higher corticosteroid exposure reflected this toxicity burden but was not associated with inferior PFS. Thus, incorporating quantitative CAR‐T enumeration into clinical practice may dynamically refine risk stratification post‐infusion and guide individualised management, such as the frequency of monitoring for progressive disease in the era of effective subsequent therapies.
- 7 September 2026
- Published by Wiley in British Journal of Haematology
Open AccessDynamic risk stratification using early CAR ‐T expansion in R/R LBCL treated with axicabtagene ciloleucel
Summary: The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T‐cell expansion post‐infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B‐cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi‐cel). CAR T‐cell expansion was measured by flow cytometry at days 7, 14 and 28 following infusion with real‐time reporting to the clinical service in 111 patients. We examined the association between CAR T‐cell expansion, efficacy (progression‐free survival [PFS]), toxicity (cytokine release syndrome [CRS] and immune effector cell‐associated neurotoxicity syndrome [ICANS]) and toxicity management, accounting for baseline risk factors. A multivariable model combining day 7 expansion with pre‐lymphodepletion lactate dehydrogenase (LDH) and bridging response demonstrated that robust day 7 expansion (≥48 cells/μL) was independently associated with improved PFS (hazard ratio [HR], 0.43; 95% confidence interval [CI] 0.22–0.83; p = 0.01). Higher day 7 expansion was associated with increased CRS severity and ICANS incidence. Higher corticosteroid exposure reflected this toxicity burden but was not associated with inferior PFS. Thus, incorporating quantitative CAR‐T enumeration into clinical practice may dynamically refine risk stratification post‐infusion and guide individualised management, such as the frequency of monitoring for progressive disease in the era of effective subsequent therapies.